HOT OFF THE WIRE

Breaking News

Tweet TWEET

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference  WALTHAM, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Cowen and Company 34^th Annual Healthcare Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.  A live audio webcast of the discussion will be accessible through the Investors section of the company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days.  About AMAG  AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical company, supported by a talented and passionate workforce. AMAG currently markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. The company's primary goal is to bring to market therapies that provide clear benefits and improve patients' lives. For additional company information, please visit www.amagpharma.com.  AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard is a registered trademark of Access Pharmaceuticals, Inc.  CONTACT: AMAG Pharmaceuticals, Inc. Contact:          Amy Sullivan, 617-498-3303  AMAG Pharmaceuticals logo